Viracta Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides a Corporate Update
Final Phase 1b/2 data showing promising and durable signal of efficacy for Nana-val in patients with relapsed/refractory Epstein-Barr virus-positive (EBV+)...
United States Ivor Royston Ashleigh Barreto Silicon Valley Bank Shenzhen Salubris Pharmaceutical Co Exchange Traded Funds Etfs
Source: prnewswire.com